Revenue
2019
2020
2021
2022
2023
2024
2025
Shattuck Labs, Inc. (STTK)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $5.7M | $1.7M | $652,000 | $30.0M | $9.9M | $9.9M |
| Research & development | $35.3M | $67.2M | $74.3M | $82.9M | $56.6M | $37.5M | $29.2M |
| Operating expenses | $52.5M | $86.3M | $93.6M | $104.0M | $75.3M | $46.9M | $35.0M |
| Operating income | −$51.5M | −$80.6M | −$92.0M | −$103.3M | −$45.3M | −$36.9M | −$25.1M |
| EBITDAderived | −$47.8M | −$76.8M | −$88.0M | −$100.2M | −$43.9M | −$36.3M | −$24.6M |
| Net income | −$48.8M | −$75.4M | −$87.3M | −$101.9M | −$45.0M | −$36.6M | −$24.0M |
| Basic EPSper diluted share | -$0.70 | -$1.49 | -$2.05 | -$2.41 | -$1.07 | -$2.36 | -$3.17 |
| Diluted EPSper diluted share | -$0.70 | -$1.49 | -$2.05 | -$2.41 | -$1.07 | -$2.36 | -$3.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 | Ashiya MonaDirector | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 208.3K | — | — | 5.30M |
| Jun 11, 2026Form 4 | Ashiya MonaDirector | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 1.04M | — | — | 26.52M |
| Jun 11, 2026Form 4 | ORBIMED ADVISORS LLC +2Director | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 208.3K | — | — | 5.30M |
| Jun 11, 2026Form 4 | ORBIMED ADVISORS LLC +2Director | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 1.04M | — | — | 26.52M |
| Jun 9, 2026Form 4 | SIEGALL CLAY BDirector | BuyCommon Stock | 62.5K | $4.00 | $250.0K | 318.6K |